Patient Enrollment

Impel NeuroPharma enrolls last patient in phase 3 migraine trial of INP104

Impel NeuroPharma announced the last patient has been enrolled in "STOP-301" (Safety and Tolerability of POD-DHE), the Company's pivotal open-label Phase 3, multi-use, long-term safety and tolerability of INP104 for the treatment of acute migraine.

Kedrion Biopharma announces enrollment of first patient in CARES10 trial

Kedrion Biopharma, an international specialist in the manufacture and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, today announced initiation of the CARES10 (Clinical Assessment of phaRmacokinetics, Efficacy, Safety of a 10% Ig) clinical study.

Biohaven enrolls first patient in phase 3 Spinocerebellar Ataxia clinical trial of Troriluzole

Biohaven Pharmaceutical Holding Company, a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, has enrolled the first patient in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in Spinocerebellar Ataxia (SCA).

Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure

Amgen, Cytokinetics, and Servier announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment.

Newron completes patient enrollment in STARS Study

Newron Pharmaceuticals has announced the successful completion of patient enrollment in its STARS (Sarizotan for the Treatment of Apneas in Rett Syndrome) clinical study.

Vaccinex completes enrollment for SIGNAL Huntington’s disease trial

Vaccinex has completed subject enrollment for the SIGNAL trial, which is a phase 2, multi-center, randomized, double-blind, placebo controlled study in subjects with early manifest and late prodromal Huntington’s disease (HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503 (pepinemab).

Actinogen Medical enrolls last patient in phase 2 Alzheimer’s trial

Actinogen Medical has enrolled the final patient into XanADu, a phase 2 clinical trial to evaluate Xanamem in the treatment of patients with mild Alzheimer’s disease.

4D pharma begins patient enrollment in Blautix IBS phase II study

UK-based 4D pharma has commenced patient enrollment for a phase 2 clinical trial to evaluate its single-strain live biotherapeutic candidate Blautix to treat Irritable Bowel Syndrome (IBS).

Verona enrolls last patient in phase 2 trial for RPL554 in COPD

Verona Pharma has completed patient enrollment for a phase 2 trial for its nebulized RPL554 as an add-on to dual therapy using long-acting anti-muscarinic / long-acting beta2-agonists (LAMA/LABA) and triple therapy (LAMA/LABA with an inhaled corticosteroid) in the maintenance treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD).